Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation

Immunology

Volumn 120, Issue 1, 2007, Pages 133-139

  Dupont, Peter J ^a   Warrens, Anthony N ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Fas ligand; Immune privilege; Neutrophil; Transplantation

Indexed keywords

FAS LIGAND; MATRIX METALLOPROTEINASE; RECOMBINANT PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CELL MEMBRANE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DOWN REGULATION; INFLAMMATION; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 33845658332     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02504.x     Document Type: Article

References (30)

1. van Dooremal J. Akbrecg. Vab Graefes Arch Ophthalomol 1873; 19:358-73.
2. Niederkorn JY. The immune privilege of corneal allografts. Transplantation 1999; 67:1503-8.
3. Niederkorn JY, Streilein JW, Kripke ML. Promotion of syngeneic intraocular tumor growth in mice by anterior chamber-associated immune deviation. J Natl Cancer Inst 1983; 71:193-9.
4. Jiang LQ, Streilein JW. Immune privilege extended to allogeneic tumor cells in the vitreous cavity. Invest Ophthalmol Vis Sci 1991; 32:224-8.
5. Ksander BR, Streilein JW. Immune privilege to MHC-disparate tumor grafts in the anterior chamber of the eye. I. Quantitative analysis of intraocular tumor growth and the corresponding delayed hypersensitivity response. Transplantation 1989; 47:661-7.
6. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377:630-2.
7. Filippini A, Riccioli A, Padula F, et al. Control and impairment of immune privilege in the testis and in semen. Hum Reprod Update 2001; 7:444-9.
8. Selawry HP, Cameron DF. Sertoli cell-enriched fractions in successful islet cell transplantation. Cell Transplant 1993; 2:123-9.
9. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997; 46:317-22.
10. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273:109-12.
11. Li XK, Okuyama T, Tamura A, et al. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation 1998; 66:1416-23.
12. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3:738-43.
13. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94:3943-7.
14. Yagita H, Seino K, Kayagaki N, Okumura K. CD95 ligand in graft rejection. Nature 1996; 379:682.
15. Seino K, Kayagaki N, Fukao K, Okumura K, Yagita H. Rejection of Fas ligand-expressing grafts. Transplant Proc 1997; 29:1092-3.
16. Ottonello L, Tortolina G, Amelotti M, Dallegri F. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol 1999; 162:3601-6.
17. Kang SM, Lin Z, Ascher NL, Stock PG. Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection. Transplant Proc 1998; 30:538.
18. O'Connell J. Immune privilege or inflammation? The paradoxical effects of Fas ligand. Arch Immunol Ther Exp (Warsz) 2000; 48:73-9.
19. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187:1205-13.
20. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998; 4:31-6.
21. Boyum A. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field. Scand J Clin Lab Invest Suppl 1968; 97:51-76.
22. Sieg S, Smith D, Kaplan D. Differential activity of soluble versus cellular Fas ligand: regulation by an accessory molecule. Cell Immunol 1999; 195:89-95.
23. Holler N, Tardivel A, Kovacsovics-Bankowski M, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003; 23:1428-40.
24. Seino K, Iwabuchi K, Kayagaki N, et al. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998; 161:4484-8.
25. Bouchet D, Tesson L, Menoret S, Charreau B, Mathieu P, Yagita H, Duisit G, Anegon I. Differential sensitivity of endothelial cells of various species to apoptosis induced by gene transfer of fas ligand: role of flip levels. Mol Med 2002; 8:612-23.
26. Kang SM, Braat D, Schneider DB, et al. A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. Transplantation 2000; 69:1813-7.
27. Hohlbaum AM, Gregory MS, Ju ST, Marshak-Rothstein A. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol 2001; 167:6217-24.
28. Lloyd AR, Oppenheim JJ. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol Today 1992; 13:169-72.
29. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4:1287-92.
30. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998; 282:1714-7.